The short version of research peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
== Personal life == In the early 1990s, Staley enrolled in several rehab programs, but he failed to stay clean for long. At one point, the other members of Alice in Chains flew to Los Angeles for weekly therapy at Staley's rehab. During the Dirt tour, Alice in Chains' manager, Susan Silver, hired bodyguards to keep Staley away from people who might try to pass him drugs, but he ended up relapsing on alcohol and drugs during the tour. Screaming Trees' Mark Lanegan recalled partying with Staley on tour and said that, "off stage, it was an insane, dark, drug and alcohol-fuelled frat party from start to finish, with Layne [Staley] and I raising hell, behaving like teenagers, staying up for days on end. We partook of whatever drugs came our way. Heroin, cocaine, painkillers, anything." Kurt Cobain's death in April 1994 scared Staley into temporary sobriety, but soon he was back into his addiction. Alice in Chains' managers turned down lucrative touring possibilities and kept the band off the road, hoping that would help Staley. Pearl Jam lead guitarist Mike McCready also tried to help Staley by inviting him to his side project, Mad Season. McCready had hoped that playing with sober musicians would encourage Staley. On October 29, 1996, Staley's former fiancée, Demri Lara Parrott, died of a drug overdose. Staley was placed on a 24-hour suicide watch, according to NME, which quoted a friend saying Staley was taking Parrott's death "extremely badly" and had fallen into a deep depression. Lanegan told Rolling Stone in 2002, "He never recovered from Demri's death.
==== Branding irons ==== Freeze brands are distinct from hot branding irons, which are generally made from steel or cast iron. Freeze brands at their working temperature possess a smaller difference in temperature from 25 °C than hot brands (−72 °C to −196 °C vs +500 °C). They must therefore be applied for much longer durations—up to 1 minute, compared to 3–5 seconds for hot branding. Further, the rapid removal of heat fundamentally differs from the sudden addition of heat, both in its physiological effects and the time required to achieve a given change in temperature. To compensate for these disadvantages the thermal conductivity of the brand is far more important in freeze branding than it is in hot branding. Freeze brands are occasionally made from pure copper but are more often made of a cupronickel alloy. This alloy was selected to exploit copper's high thermal conductivity (only diamond and silver are better heat conductors) and nickel's ability to extend copper's high thermal conductivity into cryogenic temperature regimes. Maximum thermal conductivity is desirable because it directly controls how long the supercooled iron must be pressed to the animal's skin. For this reason, steel, brass, bronze and aluminum cryogenic brands are no longer widely used. Commercial freeze brands generally have a stamp on the stem end indicating what shape of the brand will be produced. This allows the user to select the right brand from the coolant bath without lifting each out to inspect its face.
=== Analogues === Analogues of 4-HO-MET include psilocin (4-HO-DMT), 4-HO-DET (ethocin), 4-HO-MiPT (miprocin), 4-HO-DPT (deprocin), 4-HO-MPT (meprocin), 4-HO-DALT (dalocin), and 4-HO-MALT (malocin), among others. 4-AcO-MET (metacetin) and 4-PrO-MET are ester prodrugs of 4-HO-MET. Other analogues of 4-HO-MET include methylethyltryptamine (MET), 5-HO-MET, and 5-MeO-MET.
Sources: en.wikipedia.org
Dr. Gian Parkash Gopal. Founder, Oxford Hindu Temple and Community Centre Project. For services to the Hindu Community and to Multi-Faith Cohesion in Oxfordshire. Elizabeth Jane Gorb. Director of Apprenticeships, Manchester Metropolitan University. For services to Education and Skills. Permjit Gosal (Pam Gosal), MSP. Member of the Scottish Parliament for West Scotland. For services to Business, to Racial Equality and to Charity in Milton Keynes. David James Connelly Graham. National Director, Care Leavers Association. For services to Care Leavers. Sarah Jane Vandevelde Graham. Founder, Hilltops Ukrainian Support Community. For services to Ukrainian Refugees. The Reverend Canon Terence Kevin Declan Graham, DL. Rector, St Bartholomew's Church, Belfast. For services to the Reserve Forces and to the community in Belfast. Julie Grant. Deputy Director, News and Digital, Scottish Government. For services to Scotland on the Demise of Her Majesty Queen Elizabeth II. Dr. Simon Jonathon Grant. Technical Director, Thomas Swan. For services to Diversity in the Chemical Industry. Belinda Elizabeth Gray. Founder, Art for Cure. For services to Breast Cancer Charities. Julie Heather Gray. Founder, Adventure Activities for All Abilities. For services to Children with Impairments in Nottinghamshire. Neil Jonathan Greenwood. Executive Director, Finance and Corporate Services, Natural History Museum. For services to Museums. Robert Terence Grey. Lately Boxing Gym Owner and Trainer, Gwent Amateur Boxing Club. For services to Amateur Boxing in Swansea. Dr. John Michael Grimshaw.
== CLIA identification number == CLIA identification numbers are 10-digit alphanumeric unique identifiers issued by the CLIA data system to identify a CLIA laboratory. This is assigned at the time of initial entry of the CLIA application and included with the mailing of the remittance fee coupon.
=== Common deprotection cocktails for Fmoc during SPPS === 20% piperidine in DMF (Fmoc group has an approximate half life of 6 seconds in this solution) 5% piperazine, 1% DBU and 1% formic acid in DMF. This method avoids the use of strictly controlled piperidine. No side product was observed for a peptide with 9 residues synthesized with this method.
In 2001, various tyrannosaurid teeth and a metatarsal unearthed in a quarry near Zhucheng, China, were assigned by Chinese paleontologist Hu Chengzhi to the newly erected species Tyrannosaurus zhuchengensis. However, in a nearby site, a right maxilla and left jawbone were assigned to the newly erected tyrannosaurid genus Zhuchengtyrannus in 2011. It is possible that T. zhuchengensis is synonymous with Zhuchengtyrannus. In any case, T. zhuchengensis is considered to be a nomen dubium as the holotype lacks diagnostic features below the level Tyrannosaurinae. In 2006, a fragmentary tyrannosaurid lacrimal (CM 9401) from the Judith River Formation of Fergus County, Montana, was described as ?Tyrannosaurus sp. This isolated right lacrimal was originally collected alongside the holotype specimen of Deinosuchus rugosus, a giant crocodilian, and remained undescribed until its re-identification as belonging to a tyrannosaurid theropod in the 1980s by paleontologist Dale Russell. The lacrimal closely resembles those of Tyrannosaurus rex in both size and morphology. Notably, it lacks the "lacrimal horn" typically present in earlier tyrannosaurids like Albertosaurus and Gorgosaurus, instead exhibiting a distinct rugosity along the dorsal surface—consistent with T. rex and its Asian relative Tarbosaurus. The specimen's considerable size places it within the range of known T. rex individuals, suggesting the presence of large tyrannosaurids during the Campanian stage (~75 million years ago), a temporal range earlier than the established Maastrichtian age (~68–66 Ma) for Tyrannosaurus rex.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.